Loading...

SAGE SAGE THERAPEUTICS INC Product Launches 8-K Filing

SG T

SG

SAGE THERAPEUTICS INC

(SAGE)

2024 8-K

Show Summary

Show Summary

Earnings Releases

Management Change

Financial Results

Strategic Alternatives

Acquisition Proposal

Board Retirement

Management Changes

Financial Results

Workforce Reduction

Collaboration Termination

Financial Results Announcement

Phase 2 Study Results

Annual Meeting Approval

Financial Results Announcement

Amendment Approval

Departure of Directors

Financial Results Announcement

Special Meeting of Stockhol...

Lease Agreement

Management Changes

Sales Agreement

Financial Results Announcement

Reorganization Plan

Earnings Reports

Annual Meeting Approval

Financial Results Announcement

Appointment of Director

Financial Results Announcement

FDA Acceptance of New Drug ...

Corporate Presentation for ...

External Links:

Sage Therapeutics announced the topline results from its Phase 2 study of Dalzanemdor (SAGE-718) for treating cognitive impairment in Huntington's Disease.

AI Assistant

SAGE THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.